MLTX vs. CIFR, DCGO, EDTX, QSI, CHMI, CTLT, QGEN, PCVX, ROIV, and LNTH
Should you be buying MoonLake Immunotherapeutics stock or one of its competitors? The main competitors of MoonLake Immunotherapeutics include Cipher Mining (CIFR), DocGo (DCGO), EdtechX Holdings Acquisition Corp. II (EDTX), Quantum-Si (QSI), Cherry Hill Mortgage Investment (CHMI), Catalent (CTLT), Qiagen (QGEN), Vaxcyte (PCVX), Roivant Sciences (ROIV), and Lantheus (LNTH).
Cipher Mining (NASDAQ:CIFR) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both business services companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, community ranking, earnings and institutional ownership.
Cipher Mining has a net margin of 13.54% compared to Cipher Mining's net margin of 0.00%. MoonLake Immunotherapeutics' return on equity of 4.66% beat Cipher Mining's return on equity.
In the previous week, Cipher Mining had 3 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 7 mentions for Cipher Mining and 4 mentions for MoonLake Immunotherapeutics. Cipher Mining's average media sentiment score of 1.23 beat MoonLake Immunotherapeutics' score of 0.43 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.
Cipher Mining has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Cipher Mining, indicating that it is currently the more affordable of the two stocks.
Cipher Mining has a beta of 2.29, indicating that its share price is 129% more volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500.
12.3% of Cipher Mining shares are owned by institutional investors. Comparatively, 93.8% of MoonLake Immunotherapeutics shares are owned by institutional investors. 2.3% of Cipher Mining shares are owned by insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Cipher Mining currently has a consensus price target of $6.40, suggesting a potential upside of 9.97%. MoonLake Immunotherapeutics has a consensus price target of $79.00, suggesting a potential upside of 76.46%. Given Cipher Mining's higher probable upside, analysts plainly believe MoonLake Immunotherapeutics is more favorable than Cipher Mining.
MoonLake Immunotherapeutics received 13 more outperform votes than Cipher Mining when rated by MarketBeat users. However, 92.86% of users gave Cipher Mining an outperform vote while only 78.79% of users gave MoonLake Immunotherapeutics an outperform vote.
Summary
Cipher Mining beats MoonLake Immunotherapeutics on 11 of the 17 factors compared between the two stocks.
Get MoonLake Immunotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MoonLake Immunotherapeutics Competitors List
Related Companies and Tools
Free MLTX Stock Alerts